Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation
Folia Pharmacologica Japonica · 2023
DOI: 10.1254/fpj.22148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Folia Pharmacologica Japonica, 2023. Verfasst von Hirotoshi Hoshiyama. Beteiligte Einrichtung: Amgen K.K. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amgen K.K.
Zitieren
APA
Hoshiyama, H. (2023). Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.22148
Vancouver
Hoshiyama H. Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation. Folia Pharmacologica Japonica. 2023. doi:10.1254/fpj.22148
BibTeX
@article{Hoshiyama2023,
author = {Hoshiyama, Hirotoshi},
title = {Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation},
journal = {Folia Pharmacologica Japonica},
year = {2023},
doi = {10.1254/fpj.22148}
}
EUVIMED